**JPED-D-22-00015 – Supplementary Material**

**Supplemental material 1.** Comparison of clinical baseline data [n (%)].

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Observation group | Control group | t or χ2 | *P* |
| Age | 2.2±1.4 | 2.1±1.2 | 0.476 | 0.635 |
| Family history of illness |  |  | 1.364 | 0.243 |
| Yes | 20 (27.79) | 16 (19.75) |  |  |
| No | 52 (72.22) | 65 (80.25) |  |  |
| Gender |  |  | 0.327 | 0.568 |
| boy | 38 (52.78) | 39 (48.15) |  |  |
| girl | 34 (47.22) | 42 (51.85) |  |  |
| The way of childbirth |  |  | 0.425 | 0.515 |
| cesarean section | 30 (41.67) | 38 (46.91) |  |  |
| vaginal delivery | 42 (58.33) | 43 (53.09) |  |  |
| Only child |  |  | 0.229 | 0.632 |
| yes | 24 (33.33) | 30 (37.04) |  |  |
| no | 48 (66.67) | 51 (62.96) |  |  |
| Living environment |  |  | 0.363 | 0.547 |
| city | 58 (80.56) | 62 (76.54) |  |  |
| countryside | 14 (19.44) | 19 (23.46) |  |  |
| Nationality |  |  | 1.006 | 0.316 |
| Han | 70 (97.22) | 76 (93.83) |  |  |
| minority | 2 (2.78) | 5 (6.17) |  |  |
| Course of disease (day) |  |  |  |  |
| ≤7 | 42 (58.33) | - |  |  |
| ＞7 | 30 (41.67) | - |  |  |
| Pathogen |  |  |  |  |
| Bacterial | 23 (31.94) | - |  |  |
| Virus | 42 (58.33) | - |  |  |
| Mycoplasma pneumoniae | 7 (9.72) | - |  |  |
| X-ray classification |  |  |  |  |
| Type I | 15 (20.83) | - |  |  |
| Type II | 26 (36.11) | - |  |  |
| Type III | 22 (30.56) | - |  |  |
| Type IV | 9 (12.50) | - |  |  |
| Complications |  |  |  |  |
| Yes | 22 (30.56) | - |  |  |
| No | 50 (69.44) | - |  |  |

**Supplemental material 2.** Correlation of GP73 and G-CSF with the pathology of pediatric BP.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | n | GP73(ng/mL) | t or F/*P* | G-CSF (pg/mL) | t or F/*P* |
| **Age** |  |  | 0.294/0.770 |  | 0.003/0.997 |
| ≤2 | 47 | 74.14±10.15 |  | 114.87±24.91 |  |
| >2 | 25 | 73.42±9.36 |  | 114.89±21.66 |  |
| **Family history of illness** |  |  | 0.578/0.565 |  | 0.562/0.576 |
| Yes | 20 | 72.76±10.08 |  | 116.03±23.76 |  |
| No | 52 | 74.29±9.80 |  | 112.44±23.83 |  |
| **Course of disease(day)** |  |  | 1.319/0.192 |  | 2.905/0.005 |
| ≤7 | 42 | 72.61±9.60 |  | 108.34±22.29 |  |
| ＞7 | 30 | 75.69±10.01 |  | 124.04±22.83 |  |
| **Pathogen** |  |  | 0.347/1.074 |  | 0.796/0.229 |
| Bacterial | 23 | 74.12±9.97 |  | 114.05±23.96 |  |
| Virus | 42 | 77.02±9.84 |  | 116.17±24.55 |  |
| Mycoplasma pneumoniae | 7 | 72.52±9.72 |  | 109.86±19.15 |  |
| **X-ray classification** |  |  | 81.100/<0.001 |  | 12.770/<0.001 |
| Type I | 15 | 63.44±4.44 |  | 94.80±25.94 |  |
| Type II | 26 | 69.63±3.70\* |  | 115.69±16.31\* |  |
| Type III | 22 | 79.01±5.05\*# |  | 115.21±19.82\* |  |
| Type IV | 9 | 91.10±6.54\*#@ |  | 145.19±11.90\*#@ |  |
| **Complications** |  |  | 6.477/<0.001 |  | 3.461/0.009 |
| Yes | 22 | 82.89±8.14 |  | 129.09±24.97 |  |
| No | 50 | 69.93±7.68 |  | 109.41±20.94 |  |

Note: \* *vs.* Type Ⅰ, # *vs.* Type Ⅱ, @ *vs.* Type Ⅲ, *p <* 0.05.



**Supplemental material 3. Changes in GP73 and G-CSF before and after treatment.** (A) The levels of GP73 in the observation group before and after treatment; \* indicates p < 0.05 in comparison with before treatment. (B) The levels of G-CSF in the observation group before and after treatment; \* indicates p < 0.05 in comparison with before treatment.